ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference Presentation highlights the use ProMIS’ proprietary discovery platform to identify novel therapeutic targets on misfolded proteins in multiple neurodegenerative diseases TORONTO, Ontario and CAMBRIDGE, Massachusetts…
ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE Prion 2017: DECIPHERING NEURODEGENERATIVE DISORDERS 23 – 26 May 2017 Edinburgh ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to present at Prion 2017 International Conference TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 25, 2017– ProMIS Neurosciences, Inc., a biotechnology company…
ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 24, 2017 – ProMIS Neurosciences, a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that…
